摘要
目的:构建基于抗流感病毒活性的黄精的质量生物评价方法,筛选黄精潜在的抗流感病毒的活性物质。方法:采用气相色谱-质谱联用(GC-MS)法,建立10批黄精药材的指纹图谱;使用抗流感病毒神经氨酸酶(NA)效价试剂盒,检测黄精提取物对NA的体外抑制活性,并应用生物效价计算软件计算黄精药材的生物效价;通过SPSS软件得到指纹图谱特征峰的峰面积与生物效价值之间的相关性,从而筛选出与黄精药材的抗病毒活性的相关系数高的化合物。结果:建立28个共有峰的GC-MS指纹图谱;并得到黄精药材提取物对NA的抑制作用曲线,其效价范围为0.138 U/mg~0.649 U/mg,相关性结果表明,有13个化合物具有较高相关性。结论:建立了黄精的抗流感病毒的质量生物评价方法,使黄精的质量评价能够关联其功效;筛选出相关性高的化学成分,为揭示黄精抗病毒的药效物质,以及抗病毒药物的筛选提供依据。
Objective: To establish a bio-evaluation method based on antiviral activity for Polygonati rhizoma quality control, and to screen active components with antiviral activity from Polygonati rhizoma. Methods:Fingerprints of 10 batches of Polygonati rhizoma extractions from various sources were established by GC-MS. The anti-influenza virus neuraminidase(NA) titer kit was used to detect the in vitro inhibitory activity of the extract from Polygonati rhizoma on NA,the bioassay of Polygonati rhizoma was calculated by biological potency calculation software. The correlation between the peak area of the characteristic peaks and biological potency was obtained by SPSS software. Therefore, the compounds which have high correlation coefficient with the antiviral activity of Polygonati rhizoma were screened out. Results: 28 common Peaksin GC-MS fingerprint were established. The inhibition curve of influenza virus neuraminidase(NA) was obtained, the antiflu biopotency of the samples ranged from 0.138 to 0.649 U/mg. The spectrum-activity relationship results showed that there were 13 compounds with high correlations. Conclusion:A bio-evaluation method based on antiviral activity of Polygonati rhizoma is established, the quality evaluation of Polygonati rhizoma can be related to its efficacy. The active components with antiviral activity can be screened, it provides an effective approach for revealing the antiviral efficacy of Polygonati rhizoma and the screening of antiviral drugs.
作者
谭小青
唐红珍
高红伟
孙雪萍
刘振杰
Tan Xiaoqing;Tang Hongzhen;Gao hongwei;Sun xueping;Liu Zhenjie(Institute of Traditional Medical and Pharmaceutical Science,Nanning 530022;Guangxi University of Chinese Medicine,Nanning 530299)
出处
《中药药理与临床》
CAS
CSCD
北大核心
2021年第1期116-120,共5页
Pharmacology and Clinics of Chinese Materia Medica
基金
中国-东盟传统医药发展研究中心开放课题(编号:0501801727)。